300289.SZ
利德曼
SZSE · Healthcare · C 制造业 · CN
CNY 5.75
−3.20%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 317.9M | 326.3M | 370.2M | 461.6M | 706.0M |
| Cost of Revenue | 166.1M | 162.8M | 177.3M | 196.6M | 405.6M |
| Gross Profit | 151.8M | 163.5M | 192.9M | 264.9M | 300.4M |
| Operating Expenses | |||||
| R&D Expense | 23.0M | 24.1M | 33.0M | 36.9M | 35.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 72.9M | 75.3M | 84.3M | 89.6M | 85.6M |
| Selling & Marketing Expense | 76.0M | 78.6M | 92.6M | 93.6M | 120.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 174.8M | 182.6M | 208.8M | 219.8M | 240.8M |
| Cost and Expenses | 340.9M | 345.4M | 386.1M | 416.4M | 646.4M |
| Operating Income (EBIT) | (20.5M) | (17.5M) | (73.7M) | 23.9M | 7.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (20.5M) | (17.5M) | (73.2M) | 24.5M | (25.2M) |
| Income Tax Expense | 6.0M | 6.1M | 1.0M | 1.9M | 10.9M |
| Bottom Line | |||||
| Net Income | (25.7M) | (23.0M) | (75.1M) | 15.3M | (56.3M) |
| Earnings from Cont. Ops | (26.5M) | (23.6M) | (74.2M) | 22.7M | (36.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (25.7M) | (23.0M) | (75.1M) | 15.3M | (56.3M) |
| Per Share | |||||
| Basic EPS | (CN¥0.05) | (CN¥0.04) | (CN¥0.14) | CN¥0.03 | (CN¥0.10) |
| Diluted EPS | (CN¥0.05) | (CN¥0.04) | (CN¥0.14) | CN¥0.03 | (CN¥0.10) |
| Revenue Per Share | CN¥0.58 | CN¥0.57 | CN¥0.69 | CN¥0.90 | CN¥1.25 |
| Shares | |||||
| Basic Shares Outstanding | 544.2M | 574.6M | 536.4M | 511.2M | 562.7M |
| Diluted Shares Outstanding | 544.2M | 574.6M | 536.4M | 511.2M | 562.7M |
| Profitability Metrics | |||||
| EBITDA | — | 36.3M | (10.7M) | 90.7M | 71.5M |
| D&A | — | 53.8M | 63.0M | 66.8M | 63.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026